



**RICHARD A. FRANK, MD, PhD, FPM (RCP)**  
**VP, Clinical Strategy and Policy, GE Healthcare**  
**2010**

Dr Frank assembled one of the first Translational Medicine Departments in the therapeutic pharmaceutical industry, focusing on genomics and imaging as biomarkers of drug effects of efficacy and safety. Richard has conducted 100+ clinical trials, gaining approval for drugs in the US and EU. In GE, he assembled the clinical trials program and gained approval for novel devices in the US and EU.

Richard is active in public-private partnerships with the National Institutes of Health, FDA, and professional societies such as the Radiological Society of North America, the Society of Nuclear Medicine, and the Academy of Molecular Imaging. He is a past president of the Society of Non-invasive Imaging in Drug Development, immediate past chair of the Institute of Molecular Technology, and co-chair of the FDG-PETCT Technical Committee of RSNA's Quantitative Imaging Biomarkers Alliance. He works with the Medical Imaging Technology Alliance and the Council on Radionuclides and Radiopharmaceuticals on clinical evidentiary issues of regulatory approval and reimbursement coverage.

Richard serves on Institute of Medicine working groups and editorial boards including [Molecular Imaging and Biology](#), and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians.